Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial
Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial
复制标题
DOI：
10.1016/s0006-3223(98)00126-7
复制
发表时间：
1998-07-15
影响因子：
10.6
通讯作者：
Krebs, WB
中科院分区：
文献类型：
--
作者：
Rosenbaum, JF;Fava, M;Krebs, WB
背景资料：最近的报告描述了选择性5-羟色胺再摄取抑制剂停药后出现的不良事件，包括头晕、失眠、紧张、恶心和激越。基于氟西汀较长的半衰期，我们假设与舍曲林或帕罗西汀治疗中断相比，氟西汀治疗中断与更少的停药后出现的不良事件相关。在这项为期4周的研究中，242例接受开放标签氟西汀、舍曲林、或帕罗西汀4-24个月，用双盲安慰剂替代中断维持治疗5-8天。采用症状问卷（Se）、停药后出现的症状和体征自评量表、28项汉密尔顿抑郁量表和Montgomery-Asberg抑郁量表评定躯体不适和抗抑郁反应的稳定性。在中断治疗后，氟西汀治疗的患者比舍曲林或帕罗西汀治疗的患者发生更少的停药后紧急事件（p
Background: Recent reports describe discontinuation-emergent adverse events upon cessation of selective serotonin reuptake inhibitors including dizziness, insomnia, nervousness, nausea, and agitation. We hypothesized that interruption of fluoxetine treatment would be associated with fewer discontinuation-emergent adverse events than interruption of sertraline or paroxetine treatment, based on fluoxetine's longer half-life.Methods: In this 4-week study, 242 patients with remitted depression receiving maintenance therapy with open-label fluoxetine, sertraline, or paroxetine for 4-24 months had their maintenance therapy interrupted with double-blind placebo substitution for 5-8 days. The Symptom Questionnaire (Se), the Discontinuation-Emergent Signs and Symptoms checklist, the 28-item Hamilton Depression Rating Scale, and the Montgomery-Asberg Depression Rating Scale were used to assess somatic.distress and stability of antidepressant response.Results: Two hundred twenty patients (91%) completed the study. Following interruption of therapy, fluoxetine-treated patients experienced fewer discontinuation-emergent events than either sertraline-treated or paroxetine-treated patients (p